# Stereotactic Ablative Radiotherapy (SABR) for Low Risk Prostate Cancer With Injectable Rectal Spacer

> **NCT02353832** · PHASE2 · COMPLETED · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 44 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DEVICE:** Injectable Rectal Spacer (SpaceOAR, Duraseal or equivalent)

## Key facts

- **NCT ID:** NCT02353832
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-06
- **Primary completion:** 2018-01-29
- **Final completion:** 2021-01-05
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2022-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02353832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02353832, "Stereotactic Ablative Radiotherapy (SABR) for Low Risk Prostate Cancer With Injectable Rectal Spacer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02353832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*